ArticleDermatology and therapy2025
The ChinaSTAD Chinese Registry in Patients with Moderate-To-Severe Atopic Dermatitis Not Controlled by Topical Therapy: Baseline Characteristics, Disease Burden and Treatment.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05023668 (China Atopic Dermatitis Registry Study), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
China Atopic Dermatitis Registry Study: a Chinese Registry Study in Moderate-to-severe Atopic Dermatitis Patients Not Controlled by Topical Therapy
Who cites it
1 citing paper in PubMed.
- Factors Influencing Self-Management Behaviors in Patients with Atopic Dermatitis and Intervention Strategies: A Narrative Review.Patient preference and adherence · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn China, real-world evidence on the burden and management of moderate-to-severe atopic dermatitis (AD) is needed. The ChinaSTAD study aimed to characterise the treatment and disease and health economic burden of patients with moderate-to-severe AD uncontrolled on topical therapy in China.
methodsThe ChinaSTAD national prospective registry study enrolled individuals aged ≥ 12 years with AD, with a SCORing Atopic Dermatitis (SCORAD) score of ≥ 25, at participating hospitals. At baseline (enrolment visit), clinical status (SCORAD, Patient-Oriented Eczema Measure [POEM], Peak Pruritus Numerical Rating Scale [PP-NRS], Atopic Dermatitis Control Tool [ADCT]), health-related quality of life (Dermatology Life Quality Index [DLQI] and Children's DLQI [CDLQI]), AD treatment, and healthcare resource use in the previous year, were evaluated. Costs were estimated from the patient's perspective. Baseline visit data are reported here for the subgroup of patients who had not received prior systemic AD therapy continuously up to the point of study enrolment. Data are expressed as mean ± standard deviation unless stated otherwise.
resultsOf 2962 patients enrolled at data cut-off (31 October 2022), 2550 were included in this analysis (aged 40.2 ± 21.0 years). The baseline SCORAD was 54.4 ± 15.7; 85.6% of patients had uncontrolled AD (ADCT score ≥ 7), and DLQI and CDLQI scores were 10.9 ± 7.1 and 9.9 ± 6.3, respectively. At enrolment, patients were being treated with antihistamines (62.1% of patients), topical corticosteroids (61.3%) and topical moisturising emollients (31.3%). In the year prior, 37.5% of patients had one to three outpatient visits (cost per visit 662.3 ± 1563.4 renminbi (RMB) and 12.9% had one to three hospital admissions (cost per hospitalisation 822.4 ± 3149.2 RMB).
conclusionsPatients in China aged ≥ 12 years with moderate-to-severe AD uncontrolled on topical therapy experience considerable disease burden. CLINICALTRIAL: GOV IDENTIFIER: NCT05023668.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.